title: Efficacy and safet of pimobendan in canine heart failure caused by myxomatous mitral valve disease.
abstract: OBJECTIVE
  To evaluate the clinical efficacy and safety of pimobendan by comparing it with ramipril over a six-month period in dogs with mild to moderate heart failure (HF) caused by myxomatous mitral valve disease (MMVD).
  
  
  METHODS
  This was a prospective randomised, single-blind, parallel-group trial. Client-owned dogs (n = 43) with mild to moderate HF caused by MMVD were randomly assigned to one of two groups, which received either pimobendan (P dogs) or ramipril (R dogs) for six months. The outcome measures studied were: adverse HF outcome, defined as failure to complete the trial as a direct consequence of HF; maximum furosemide dose (mg/kg/day) administered during the study period; and any requirement for additional visits to the clinic as a direct consequence of HF.
  
  
  RESULTS
  Treatment with pimobendan was well tolerated compared with treatment with ramipril. P dogs were 25 per cent as likely as R dogs to have an adverse HF outcome (odds ratio 4.09, 95 per cent confidence interval 1.03 to 16.3, P = 0.046).
  
  
  CONCLUSIONS
  R dogs had a higher overall score and thus may have had more advanced disease than P dogs at baseline (P = 0.04). These results should be interpreted cautiously but such a high odds ratio warrants further investigation.
authors.affiliation: Royal (Dick) School of Veterinary Studies Hospital for Small Animals, University of Edinburgh, Easter Bush Veterinary Centre, Roslin, Edinburgh EH25 9RG.
authors.forename: P J
authors.initials: PJ
authors.lastname: Smith
authors.forename: A T
authors.initials: AT
authors.lastname: French
authors.forename: N
authors.initials: N
authors.lastname: Van Israël
authors.forename: S G W
authors.initials: SG
authors.lastname: Smith
authors.forename: S T
authors.initials: ST
authors.lastname: Swift
authors.forename: A J
authors.initials: AJ
authors.lastname: Lee
authors.forename: B M
authors.initials: BM
authors.lastname: Corcoran
authors.forename: J
authors.initials: J
authors.lastname: Dukes-McEwan
mesh_terms: D000818:Animals; D002316:Cardiotonic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D004562:Electrocardiography / Q000662:veterinary; D006333:Heart Failure / Q000188:drug therapy / Q000209:etiology / Q000662:veterinary*; D008943:Mitral Valve / Q000473:pathology; D008944:Mitral Valve Insufficiency / Q000150:complications / Q000188:drug therapy / Q000662:veterinary*; D016017:Odds Ratio; D011446:Prospective Studies; D011724:Pyridazines / Q000009:adverse effects / Q000627:therapeutic use*; D017257:Ramipril / Q000627:therapeutic use; D012449:Safety; D016037:Single-Blind Method; D016896:Treatment Outcome
chemical_list: D002316:Cardiotonic Agents; D011724:Pyridazines; C041648:pimobendan; D017257:Ramipril